Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly Broadens Its Alzheimer’s R&D

by Michael McCoy
April 22, 2013 | A version of this story appeared in Volume 91, Issue 16

Eli Lilly & Co. has acquired two investigational positron emission tomography tracers from Siemens Medical Solutions as part of its effort to develop treatments for Alzheimer’s disease. The tracers image tau tangles in the brain, one of two known hallmarks of the disease along with amyloid-β plaques. Lilly had been developing the antibody solanezumab to block the formation of amyloid-β, but the drug failed in clinical trials last year. The firm now says it has established R&D programs to explore both amyloid-β and tau.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.